The product is licensed by clients such as aging-in-place facilities, wellness-focused businesses, care management organizations, health systems, and employee benefits leaders.
Enterprises can deploy the solution for use with a general managed population or an at-risk population, such as seniors, postoperative patients, those with health conditions, or new mothers.
Through an easy-to-use dashboard, an enterprise can survey, message and educate its population while the connected mobile App empowers and engages patients/employees and their families through alerts, journals, reminders, surveys, instant messaging, and tailored content.
Research by the American Heart Association indicates that incorporating family support and providing easy-to-read educational material to patients and their caregivers enhance medication adherence.
Another element of the App is targeted educational assistance (TEA), a health condition education content that is auto-delivered to the App from sources such as the National Library of Medicine.
The App also includes features to increase medication adherence. The dashboard also contains population health analytics tools tailored to the needs of the enterprise.
ICMed is a mobile patient & family engagement solution.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA